Skip to main content
. 2021 Dec 17;12:797919. doi: 10.3389/fimmu.2021.797919

Figure 1.

Figure 1

Comparison of SARS-CoV-2 RBD-specific antibodies and SARS-CoV-2-specific T cell response in healthy controls and recovered children and adolescents. (A) Serological responses to recombinant RBD protein in 31 recovered COVID-19 patients with median 46.5 recovery days and ranging 29-219 days and 20 uninfected controls. Dash line indicated the anti-RBD IgG ratio reference obtained from uninfected controls. (B) Representative data of the T cell response towards SARS-CoV-2 peptide pools in controls and recovered patients. (C) (i) CD4+ and (ii) CD8+ T cell responses to SARS-CoV-2 mixed peptides in the recovered COVID-19 patients and uninfected controls. Dash line indicated the measured T cell responses reference obtained from the uninfected controls. Data are presented as mean ± SD and analyzed using two-sided Student’s t-test between control and patient groups. ***p < 0.001.